ReviewCell reports. Medicine2025
Multiplexed iPSC platform for advanced NK cell immunotherapies.
Review in Cell reports. Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Induced Pluripotent Stem Cell-Derived NK Cells as an Off-the-Shelf Platform for Cancer Immunotherapy: Opportunities, Challenges, and Clinical Translation.Stem cell reviews and reports · 2026Review
- Beyond CRISPR: next-gen precision engineering of CAR-NK cells for enhanced persistence, trafficking, and tumor eradication.Cancer cell international · 2026Review
- dNK3 cells in normal pregnancy and recurrent pregnancy loss: from molecular identity to functional imbalance.Frontiers in immunology · 2026Review
- Induced pluripotent stem cells as platforms for engineering NK cell immunotherapies.Frontiers in cell and developmental biology · 2026Review
- Dual-module aCAR-iCAR NK cells for solid tumors: cascade resistance mechanisms, AI-driven engineering, and precision stratification.Frontiers in immunology · 2026Review
- Overcoming heterogeneity and immunosuppression: novel strategies in adoptive therapy for biliary tract cancer.Frontiers in immunology · 2026Review
- Next-generation immune cell therapies for lung cancer: advances in CAR-T, NK, and TIL strategies.Frontiers in medicine · 2026Review
- Targeting the synovial engine: next-generation engineered immune cells to eradicate pathogenic FLS in rheumatoid arthritis, with safety-first, selective designs.Frontiers in immunology · 2026Review
- Targeted therapies in lung cancer: personalizing treatment across the age spectrum.Frontiers in oncology · 2026Review
- Dendritic Cell Immunotherapy for Solid Tumors: Advances in Translational Research and Clinical Application.Current issues in molecular biology · 2025Review
- Evolving frontiers in bladder cancer immunotherapy: integrating BCG, immune checkpoints, viral vectors, nanotechnology, and CAR-based therapies.Frontiers in cell and developmental biology · 2025Review
- Editorial: Achilles heel of CAR T-cell therapy.Frontiers in immunology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Human pluripotent stem cell (PSC) derivation advances have revealed enormous potential for improved cancer immunotherapy and clinical-scale blood cell production. PSCs can self-renew indefinitely and be differentiated into specialized cells, making them promising candidates for producing cytotoxic lymphocytes. Deriving natural killer (NK) cells from PSCs unlocks new possibilities for studying developmental hematopoiesis and investigating potential immunotherapy treatments. Cellular therapies, combined with genetic engineering, are potent tools for combating cancer and viral infections. While NK cells directly lyse tumor cells, genetic modifications, such as chimeric antigen receptor (CAR) engineering or the deletion of checkpoint molecules, can enhance their functional capacity. Here, we discuss recent advances in induced PSC (iPSC) editing and guided differentiation, focusing on developing NK cell immunotherapeutic products and optimizing iPSCs as an NK cell source to broaden therapeutic options and address diverse patient needs. This comprehensive review evaluates iPSC-derived NK cell-based therapies, recent advances, and future genome-editing strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.